Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 14/20 | 1.00 |
| ▸ | BMP1 | P13497 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KDM6B | O15054 | 1/20 | 0.50 |
| ▸ | KDM5C | P41229 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.50 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13996820 | 0.84 | FOLH1 (1.00) | FOLH1KDM4EKDM6BKDM5CEGLN1 | |
| SCHEMBL18309784 | 0.83 | FOLH1 (0.71) | FOLH1BMP1GRM3NAALAD2 | |
| SCHEMBL2368592 | 0.82 | FOLH1 (0.69) | FOLH1GRM3NAALAD2 | |
| SCHEMBL28640 | 0.81 | FOLH1 (1.00) | FOLH1KDM2AGRM3NAALAD2 | |
| SCHEMBL30452229 | 0.79 | FOLH1 (0.95) | FOLH1GRM3NAALAD2 | |
| SCHEMBL29506664 | 0.79 | FOLH1 (0.95) | FOLH1GRM3NAALAD2 | |
| Hydrochloric Acid SCHEMBL8841265 | 0.79 | FOLH1 (0.95) | FOLH1GRM3NAALAD2 | |
| Phosphine SCHEMBL28173645 | 0.79 | FOLH1 (0.95) | FOLH1GRM3NAALAD2 | |
| SCHEMBL29506667 | 0.79 | FOLH1 (0.95) | FOLH1GRM3NAALAD2 | |
| SCHEMBL27974419 | 0.79 | FOLH1 (0.95) | FOLH1GRM3NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064948-A1 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | THE JOHNS HOPKINS UNIVERSITY | 2025-02-27 | — | — | US | claimed |
| WO-2023154939-A2 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-17 | — | — | WO | claimed |
| EP-0973731-B1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2002-08-28 | — | — | EP | claimed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2002514185-A | — | — | 2002-05-14 | — | — | JP | claimed |
| US-20010044459-A1 | Hydroxamic acid derivatives | JACKSON PAUL F (US) | 2001-11-22 | — | — | US | claimed |
| JP-2001519809-A | — | — | 2001-10-23 | — | — | JP | claimed |
| EP-0973731-A1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-26 | — | — | EP | claimed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | claimed |
| WO-1998045256-A1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | claimed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| CN-113453720-B | Dual ligand drug conjugate and uses thereof | 同宜医药（苏州）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-4541378-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998045256-A1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885BMP1 241/4885KDM4E 3215/4885 |
| US-20010044459-A1 | Hydroxamic acid derivatives | NAALAD2, DNPEP, NAAA | FOLH1 6/4885BMP1 2410/4885KDM4E 1451/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | FOLH1 1/4885BMP1 1957/4885KDM4E 3194/4885 |
| US-20250064948-A1 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | DGKI, PGC, MPC2 | FOLH1 149/4885BMP1 4642/4885KDM4E 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.